Quick Answer
Indaptus Therapeutics, Inc. reported Stockholders Equity of $3.15 million for the year ending 2025.
- Indaptus Therapeutics, Inc. showed a decrease of -20.1% in Stockholders Equity from 2024 to 2025.
- This data is from Indaptus Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $2.69 million | Q2 2020: $2.02 million | Q3 2020: $513.00 | Q1 2021: -$829.7 thousand | Q2 2021: -$1.32 million | Q3 2021: $38.08 million | Q1 2022: $33.36 million | Q2 2022: $30.41 million | Q3 2022: $27.57 million | Q1 2023: $21.19 million | Q2 2023: $18.63 million | Q3 2023: $15.33 million | Q1 2024: $9.36 million | Q2 2024: $6.17 million | Q3 2024: $6.00 million | Q1 2025: $2.80 million | Q2 2025: -$1.67 million | Q3 2025: $4.61 million.
- Over the full 7 years of available data (2019 to 2025), Indaptus Therapeutics, Inc.'s Stockholders Equity has declined by 1.8%.
- Historical annual values: Fiscal year 2025: $3.15 million | Fiscal year 2024: $3.94 million | Fiscal year 2023: $12.08 million | Fiscal year 2022: $24.63 million | Fiscal year 2021: $35.90 million | Fiscal year 2020: -$237.7 thousand | Fiscal year 2019: $3.21 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: